Cytokinetics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

423

Employees423

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

423

Employees423

CYTK Key Statistics

Market cap

6.83B

Market cap6.83B

Price-Earnings ratio

-11.98

Price-Earnings ratio-11.98

Dividend yield

—

Dividend yield—

Average volume

1.15M

Average volume1.15M

High today

$66.07

High today$66.07

Low today

$63.60

Low today$63.60

Open price

$65.01

Open price$65.01

Volume

738.06K

Volume738.06K

52 Week high

$110.25

52 Week high$110.25

52 Week low

$25.98

52 Week low$25.98

CYTK News

TipRanks 1d

Cytokinetics Appoints Sung H. Lee as New CFO - TipRanks.com - TipRanks

Cytokinetics (CYTK) has shared an update. Sung H. Lee is set to join Cytokinetics, Incorporated as the Executive Vice President and Chief Financial Officer sta...

TipRanks 2d

Cytokinetics names Sung Lee as CFO

In a regulatory filing, Cytokinetics disclosed that on April 23, the company entered into an employment offer letter with Sung Lee, pursuant to which Lee has ag...

Yahoo Finance 4d

Cytokinetics to Announce First Quarter Results on May 8, 2024 - Yahoo Finance

Cytokinetics, Incorporated SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is...

Analyst ratings

83%

of 18 ratings

Buy

83.3%

Hold

16.7%

Sell